Av Meditech Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 16-11-2024
- Paid Up Capital ₹ 4.22 M
as on 16-11-2024
- Company Age 18 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.00 Cr
as on 16-11-2024
- Revenue %
(FY 2023)
- Net Worth 397.25%
(FY 2023)
- Total Assets 358.19%
(FY 2023)
About Av Meditech
The Corporate was formerly known as Astha Instiute Of Medical Training And Research Pvt Ltd. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 4.22 M.
The company currently has active open charges totaling ₹4.00 Cr.
Deepak Aggarwal, Bhawna Aggarwal, Manika Goel, and Two other members serve as directors at the Company.
- CIN/LLPIN
U85110CH2006PTC030370
- Company No.
030370
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Jun 2006
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- LocationU T, Chandigarh
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Av Meditech?
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Deepak Aggarwal  | Director | 22-Jun-2023 | Current |
| Bhawna Aggarwal | Director | 01-Aug-2023 | Current |
| Manika Goel | Director | Current | |
| Vansh Aggarwal | Director | Current | |
| Sharad Verma | Director | 02-May-2024 | Current |
Financial Performance of Av Meditech.
Av Meditech Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth Soared by an impressive increase of 397.25%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Av Meditech?
Unlock access to Av Meditech's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹40.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 4.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 27 Feb 2024 | Others | ₹4.00 Cr | Open |
How Many Employees Work at Av Meditech?
Unlock and access historical data on people associated with Av Meditech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Av Meditech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Av Meditech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
